SCHEMBL30778591

SCHEMBL30778591

Nc1ccc2cnn(C3CCCC3)c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.43
MAPT P10636 2/20 0.43
GFER P55789 2/20 0.43
ALDH1A1 P00352 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
PIK3CD O00329 11/20 0.41
PDE9A O76083 2/20 0.40
MEN1 O00255 1/20 0.40
RGS12 O14924 1/20 0.40
NPC1 O15118 1/20 0.40
USP2 O75604 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40
HTR1A P08908 1/20 0.39
HTR1B P28222 1/20 0.39
HTR1F P30939 1/20 0.39
SCD O00767 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3369338 0.93 PIK3CD (0.43) KDM4EMAPTGFERALDH1A1TDP1
SCHEMBL3351612 0.92 OGFRL1 (0.40) KDM4EMAPTGFERALDH1A1TDP1
SCHEMBL25240863 0.86 PIK3CD (0.55) PIK3CD
SCHEMBL1869336 0.86 MEN1 (0.49) MAPTALDH1A1TDP1PIK3CDMEN1
SCHEMBL29200978 0.86 KDM4E (0.49) KDM4EMAPTGFERALDH1A1TDP1
SCHEMBL3349663 0.85 HTR1B (0.54) PIK3CDHTR1AHTR1BHTR1FSCD
SCHEMBL31482830 0.84 PDE9A (0.39) PIK3CDPDE9AHTR1AHTR1BHTR1F
SCHEMBL3351511 0.82 HTR1A (0.41) KDM4EMAPTGFERPIK3CDHTR1A
SCHEMBL3352822 0.82 HTR1A (0.41) PIK3CDHTR1AHTR1BHTR1FSCD
SCHEMBL2980987 0.81 PIK3CD (0.41) PIK3CDPDE9AHTR1AHTR1BHTR1F

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062416-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS INC (US) 2026-03-05 US disclosed
WO-2024035950-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2024-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062416-A1 INHIBITORS OF KIF18A AND USES THEREOF KIF18A, KIF18B, KIF5B KDM4E 3550/4885MAPT 1276/4885GFER 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.